Table 1

Demographic and clinical characteristics of patients with primary Sjögren´s syndrome

Variable

Control

(n = 25)

All

pSS patients

(n = 50)

Clinically active

pSS patients

(n = 17)

Clinically inactive

pSS patients

(n = 33)

Serologically active

pSS patients

(n = 29)

Serologically inactive

pSS patients

(n = 18)

Clinically and serologically active pSS patients

(n = 12)

Clinically active and serologically inactive

pSS patients

(n = 4)

Clinically inactive and serologically active pSS patients

(n = 17)

Clinically and serologically inactive pSS patients

(n = 14)


Demographic

Age (years)

Mean ± SD

Median

Range

49.1 ± 11.0

48.5

23 to 75

53.1 ± 12.2

53.0

30 to 77

50.4 ± 11.8

48.5

30 to 73

54.4 ± 12.4

53.0

33 to 77

51.1 ± 10.0

50.0

33 to 73

55.1 ± 14.6

56.0

30 to 77

50.6 ± 10.7

48.0

33 to 73

51.5 ± 17.3

52.0

30 to 72

51.8 ± 10.3

51.5

33 to 72

56.2 ± 14.3

58.0

34 to 77

Sex (female/male)

20/5

48/2

16/1

32/1

28/1

17/1

12/0

3/1

16/1

14/0

Clinical

SSDAI

Mean ± SD

Median

Range

0.9 ± 1.5

0.0

0 to 6

2.5 ± 1.6

3.0

0 to 6

0.1 ± 0.3

0.0a

0 to 1

1.3 ± 1.7

1.0

0 to 6

0.4 ± 0.85

0.0

0 to 3

2.8 ± 1.6

3.0

1 to 6

1.5 ± 1.3

1.5

0 to 3

0.2 ± 0.4

0.0

0 to 1

0.1 ± 0.3

0.0

0 to 1

ESSSDAI

Mean ± SD

Median

Range

1.5 ± 1.3

1.0

0 to 5

2.6 ± 1.2

2.0

1 to 5

0.9 ± 0.9

1.0 a

0 to 3

2.0 ± 1.1

2.0

1 to 5

0.4 ± 0.9

0.0

0 to 3

2.8 ± 1.2

2.5

1 to 5

1.8 ± 1.0

1.5

1 to 3

1.5 ± 0.6

1.0

1 to 3

0.0 ± 0.0

0.0d

0 to 0

Laboratory

ESR (mm Hg)

Mean ± SD

Median

Range

21.3 ± 16.3

15.0

2 to 73

23.9 ± 15.7

22.0

2 to 59

19.5 ± 16.9

14.0

4 to 73

28.6 ± 18.0

26.0

6 to 73

12.1 ± 8.4

9.5b

2 to 29

29.8 ± 14.6

27.0

8 to 59

7.0 ± 3.4

8.5c

2 to 9

27.3 ± 21.8

16.0

6 to 73

13.8 ± 8.9

12.5

4 to 29

Serum IgM (mg/dL)

Mean ± SD

Median

Range

208.1 ± 169.8

178.5

28 to 1170

186.1 ± 70.2

179.5

52 to 303

219.8 ± 204.3

178.5

28 to 1170

204.3 ± 90.1

186.0

70 to 553

214.6 ± 258.4

146.0

28 to 1170

198.3 ± 65.5

201.0

96 to 303

149.5 ± 80.9

148.0

52 to 250

208.5 ± 105.9

182.0

70 to 553

234.6 ± 292.5

137.0

28 to 1,170

Serum IgG (mg/dL)

Mean ± SD

Median

Range

1779.8 ± 703.9

1,554.0

639 to 3,224

1973.4 ± 782.2

1,948.0

825 to 3,029

1676.6 ± 648.6

1,531.0

639 to 3,324

2092.1 ± 690.9

2,087.0

674 to 3,224

1247.1 ± 282.6

1,310.0b

639 to 1,738

2261.7 ± 678.5

2,461.0

1,177 to 3,029

1108.5 ± 203.7

1,149.5c

825 to 1,310

1972.4 ± 694.4

2,028.0

674 to 3,224

1289.8 ± 296.2

1,330.0d

639 to 1,738

Serum IgA (mg/dL)

Mean ± SD

Median

Range

345.7 ± 211.6

305.0

128 to 1420

394.1 ± 319.9

290.5

147 to 1420

319.9 ± 120.8

308.5

128 to 584

396.9 ± 248.9

343.0

128 to 1,420

258.5 ± 68.9

259.0

147 to 419

446.6 ± 355.8

337.0

176 to 1,420

236.8 ± 60.3

261.5

147 to 277

361.8 ± 135.0

353.0

128 to 584

265.2 ± 72.2

240.0

175 to 419

Serum hyperviscosity (AU)

Mean ± SD

Median

Range

2.0 ± 0.5

1.9

1.6 to 4.3

2.2 ± 0.6

2.1

1.7 to 4.3

1.9 ± 0.3

1.8

1.6 to 2.5

2.2 ± 0.5

2.1

1.7 to 4.3

1.8 ± 0.1

1.8b

1.6 to 2.0

2.3 ± 0.7

2.2

1.7 to 4.3

1.8 ± 0.2

1.7c

1.7 to 2.0

2.0 ± 0.3*

1.9

1.7 to 2.5

1.8 ± 0.1

1.8d

1.6 to 2.0

C3 (mg/dL)

Mean ± SD

Median

Range

96.4 ± 23.6

92.6

53 to 147

92.1 ± 24.5

91.5

53 to 135

98.3 ± 23.3

92.9

60 to 147

88.5 ± 22.3

81.4

53 to 143

108.7 ± 19.9

105.8b

77 to 147

88.7 ± 26.5

83.4

53 to 135

103.2 ± 14.2

99.0

92 to 119

88.4 ± 20.4

81.4

60 to 143

110.1 ± 21.3

106.4d

77 to 147

C4 (mg/dL)

Mean ± SD

Median

Range

19.8 ± 6.8

19.0

2 to 33

18.6 ± 9.6

19.1

2 to 33

20.3 ± 5.3

18.9

11 to 33

17.7 ± 6.8

18.6

2 to 33

23.6 ± 5.4

24.0c

15 to 33

16.8 ± 10.2

18.5

2 to 33

24.4 ± 4.6

26.0

19 to 25

18.3 ± 4.0

18.6

11 to 51

23.4 ± 5.7

24.0

15 to 33

Leucocytes (cells/μL)

Mean ± SD

Median

Range

6.4 ± 1.3

6.3

4.7--8.5

5.7 ± 2.0

5.5

1.5 to 12.6

5.6 ± 2.7

5.4

1.5 to 12.6

5.7 ± 1.7

5.7

3.0 to 10.7

5.1 ± 1.6

5.2

1.5 to 8.2

6.6 ± 2.5

6.2

3.9 to 12.6

4.8 ± 1.9

4.7

1.5 to 8.1

8.4 ± 3.4

7.8

5.2 to 12.6

5.4 ± 1.3

5.6

3.0 to 8.2

6.2 ± 2.0

6.0

3.9 to 10.7

Hemoglobin (g/dL)

Mean ± SD

Median

Range

14.9 ± 0.8

14.9

13.3--16.5

13.9 ± 1.4

14.1

9.9 to 17.8

14.4 ± 1.3

14.0

12.7 to 17.8

13.7 ± 1.4

14.1

9.9 to 15.9

13.9 ± 1.1

14.0

12.1 to 15.9

14.1 ± 1.8

14.5

9.9 to 17.8

13.9 ± 0.7

14.0

12.7 to 15.0

16.1 ± 1.4

15.8 c

14.9 to 17.8

13.8 ± 1.3

14.1

12.1 to 15.9

13.6 ± 1.5

14.3

9.9 to 15.1

Platelets (cells/μL)

Mean ± SD

Median

Range

264.2 ± 51.1

225.9

172--331

229.1 ± 68.1

229.5

73 to 367

233.7 ± 95.6

195.0

73 to 367

231.9 ± 50.0

231.0

149 to 357

223.9 ± 68.9

222.0

82 to 367

228.1 ± 69.3

221.0

73 to 357

240.2 ± 98.2

234.5

82 to 367

153.0 ± 56.8

172.0c

73 to 195

212.4 ± 36.7

222.0

154 to 279

249.5 ± 57.5

245.5

149 to 357

Lymphocytes (%)

Mean ± SD

Median

Range

31.1 ± 6.2

32.0

20.3--39.7

30.0 ± 10.8

28.0

9.0 to 58.0

29.9 ± 12.5

29.3

12.9 to 58

30.0 ± 9.9

27.5

9.0 to 52.3

31.1 ± 10.2

29.3

13.1 to 58.0

27.7 ± 12.3

26.5

9.0 to 52.3

33.5 ± 12.5

29.9

13.1 to 58.0

19.1 ± 7.3

18.2c

12.9 to 27.0

29.5 ± 8.1

28.5

18.2 to 48.0

30.2 ± 12.5

27.1

9.0 to 52.3

Monocytes (%)

Mean ± SD

Median

Range

8.0 ± 3.6

7.2

3 to 27

8.7 ± 5.2

7.1

5 to 27

7.6 ± 2.4

7.2

3 to 14

8.3 ± 4.2

7.8

5 to 27

7.4 ± 2.1

6.7

4 to 12

8.5 ± 6.0

7.1

5 to 27

7.9 ± 1.7

8.0

6 to 10

8.2 ± 2.4

8.0

5 to 14

7.2 ± 2.3

6.7

4 to 12

Polymorphonuclear cells(%)

Mean ± SD

Median

Range

58.9 ± 11.8

61.9

15.0 to 79.5

59.5 ± 15.2

63.0

15.0 to 79.5

58.7 ± 9.8

61.7

38.8 to 76.0

57.3 ± 11.9

60.4

15.0 to 78.1

62.1 ± 12.0

64.4

38.8 to 79.5

56.0 ± 16.2

60.4

15.0--78.1

70.9 ± 6.9

70.6

63.0 to 79.5

58.3 ± 8.0

60.4

40.0 to 68.8

59.6 ± 12.2

63.5

38.8 to 76.0


Control, control group of healthy individuals. aP < 0.05: patients with clinically active versus clinically inactive primary Sjögren's syndrome (pSS); bP < 0.05: patients with serologically active versus serologically inactive pSS; cP < 0.05: patients with clinically and serologically active versus clinically active but serologically inactive pSS; dP < 0.05: patients with clinically inactive but serologically active versus clinically and serologically inactive pSS. SSDAI, Sjögren's syndrome disease activity index; ESSSDAI, European League Against Rheumatism (EULAR) Sjögren's syndrome disease activity index; ESR, erythrocyte sedimentation rate; Ig, immunoblobulin.

Furuzawa-Carballeda et al. Arthritis Research & Therapy 2013 15:R68   doi:10.1186/ar4245

Open Data